Adapalene
Based on 5 publication(s) in Google Scholar
Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 106685-40-9
- Formula: C28H28O3
- Molecular Weight:412.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Adapalene
More-
Flow Cytometry
Biological Activity
AC50: 2.3 nM (RARβ), 9.3 nM (RARγ), and 22 nM (RARα)[1]
Adapalene (1-200 μM; 24 h) inhibits the viability of ES-2, HOV-7, MCF-7?, Hela, SW1990, HT1080, and MM-468 cells, with IC50s of 10.36 μM, 10.81 μM, 12.00 μM, 19.08 μM, 19.52 μM, 21.70 μM, and 31.47 μM, respectively[2].
?
Adapalene (10-40 μM; 24 h) induces ES-2 cells apoptosis and inhibits proliferation in vitro[2].
?
Adapalene (3-30 μM; 6-24 h) significantly increases the G1-phase population in LoVo or DLD1 cells[3].
?
Adapalene (1-200 μM) inhibits GOT1 activity, with an IC50?of 21.79?μM[2].
?
Adapalene (10-6-10-3 nM) inhibits the expression of plasma membrane-associated enzyme transglutaminase Type I, with an IC50 of 2.5 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Pancreatic cancer (SW1990, Aspc-1), breast cancer (mm-231, mm-468, MCF-7), liver cancer (Hep3B), cervical cancer (Hela), ovarian cancer (HOV-7, ES-2), normal cells (CHO, L929)
-
Concentration:1-200 μM
-
Incubation Time:24 hours
-
Result:Inhibited the viability of cancer cells with higher GOT1 protein expression.
-
Cell Line:ES-2 cells[2]
-
Concentration:10, 20, 40 μM
-
Incubation Time:24 hours
-
Result:Showed a significant increase in apoptosis compared with the control group.
Down regulated the expression of anti-apoptotic protein Bcl-2 and PARP.
-
Cell Line:LoVo or DLD1 cells
-
Concentration:3, 10, 30 μM
-
Incubation Time:6, 12, 24 hours
-
Result:Caused cell cycle arrest in G1 phase in a dose- and time-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/C nude mice (15 g, 4-5 weeks) were injected with DLD1 cells[3]
-
Dosage:15, 20, 65, 100 mg/kg
-
Administration:P.o. daily for 21 days
-
Result:Significantly reduced tumor weight and volume.
Chemical Information
-
CAS No. 106685-40-9
-
Appearance Solid
-
Molecular Weight 412.52
-
Formula C28H28O3
-
Color White to off-white
-
SMILES
COC1=C(C23CC4CC(C3)CC(C2)C4)C=C(C5=CC6=C(C=C(C(O)=O)C=C6)C=C5)C=C1
-
Synonyms
CD271
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity. [Abstract]2025 Nov 27:e09340. PMID: 41309490
Adapalene purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 27:e09340. [Abstract]
Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h.
-
Proc Natl Acad Sci U S A
2021 Jan 12;118(2):e2009539118. PMID: 33376206 -
Eur J Pharmacol
Adapalene suppressed the proliferation of melanoma cells by S-phase arrest and subsequent apoptosis via induction of DNA damage. [Abstract]2019 May 15:851:174-185. PMID: 30836068 -
Fundam Clin Pharmacol
The third-generation retinoid adapalene triggered DNA damage to induce S-phase arrest in HaCat cells. [Abstract]2020 Jun;34(3):380-388. PMID: 31808972 -
Solvent & Solubility
DMSO : 10 mg/mL (24.24 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1 mg/mL (2.42 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shroot B, et, al. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103. [Content Brief]
[2]. Wang Q, et, al. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1. Bioorg Chem. 2019 Dec;93:103315. [Content Brief]
[3]. Shi XN, et, al. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. Mol Med Rep. 2015 Nov;12(5):6501-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4241 mL | 12.1206 mL | 24.2412 mL | 60.6031 mL |
| 5 mM | 0.4848 mL | 2.4241 mL | 4.8482 mL | 12.1206 mL | |
| 10 mM | 0.2424 mL | 1.2121 mL | 2.4241 mL | 6.0603 mL | |
| 15 mM | 0.1616 mL | 0.8080 mL | 1.6161 mL | 4.0402 mL | |
| 20 mM | 0.1212 mL | 0.6060 mL | 1.2121 mL | 3.0302 mL |